CTNNB1 and metastatic prostate carcinoma: Recently, a panel of patient-derived organoids (PDOs) was generated from both primary and metastatic prostate cancer specimens, and notably, the P20-11-Lg PDO line derived from a hormone naïve prostate cancer lung metastasis sample harbors an activating CTNNB1 mutation (p-Ser45Pro) in addition to TMPRSS2-ERG fusion and PTEN genetic alterations (pThr319fs and c.209 + 2T > A), thus providing a valuable clinically relevant model [210].